The US has ordered an additional 2.5 million doses of monkeypox vaccine from Bavarian Nordic (OTCPK:BVNKF).
This comes on top of another 2.5 million dose order for Jynneos from earlier this month and a 500,000 order in June.
Appear on Bloomberg TV On Friday afternoon, the director of the National Institute of Allergy and Infectious Diseases, Anthony Fauci, said the arrival of more vaccines was imminent. “Hopefully we’ll have hundreds of thousands more doses in the next week or so,” he added.
As the number of cases of monkeypox in the U.S. rises — there were 1,470 as of July 14, according to CDC data — demand for the vaccine is increasing. In the US, there were widespread reports of demand far exceeding supply.
Fauci said the priority is to vaccinate those most at risk, whom he identified as men who have sex with men.
In response to a question, Fauci seemed opposed to using Chimerix’ (NASDAQ:CMRX) Smallpox antiviral Tembexa (brincidofovir) used to treat monkeypox. Although the CDC initiated an expanded access protocol for the drug, it has some serious side effects.
Instead, Fauci prefers SIGA Technologies’ (NASDAQ:SIGA) TPOXX (Tecovirimat), approved for smallpox in 2018 and co-developed with the National Institutes of Health.
Earlier this week, SIGA (SIGA) announced it has received approximately $28 million in orders for TPOXX.
Dear readers: We recognize that politics often overlaps with the financial news of the day, so we invite you to click here to join the separate political discussion.
https://seekingalpha.com/news/3857278-us-orders-25m-more-bavarian-nordic-monkeypox-vaccine-doses-bloomberg?utm_source=feed_news_all&utm_medium=referral U.S. orders 2.5M more Bavarian Nordic monkeypox vaccine doses – Bloomberg (NASDAQ:SIGA)